Ligand Pharmaceuticals | LGND - Equity Capital And Reserves


Ligand Pharmaceuticals reported $950.17M in Equity Capital and Reserves for its fiscal quarter ending in September of 2025.





Equity Capital And Reserves Change Date
Agenus USD -274.14M 80.46M Sep/2025
Amgen USD 8.66B 961M Dec/2025
Anika Therapeutics USD 146.8M 867K Sep/2025
Arrowhead Research USD 568.42M 102.37M Dec/2025
Baxter International USD 6.13B 1.11B Dec/2025
Bristol-Myers Squibb USD 18.55B 1.06B Sep/2025
Eli Lilly USD 26.54B 2.74B Dec/2025
Enanta Pharmaceuticals USD 126.59M 61.87M Dec/2025
Enviri Corporation USD 361.08M 15.18M Sep/2025
Gilead Sciences USD 22.62B 1.16B Dec/2025
GlaxoSmithKline GBP 16.38B 229M Dec/2025
Glaxosmithkline GBP 21.7B 7.35B Sep/2025
Heron Therapeutics USD 14.88M 42.14M Sep/2025
Insmed USD 738.98M 206.6M Dec/2025
Intrexon USD 43.17M 75.33M Jun/2024
Ionis Pharmaceuticals USD 617.97M 13.76M Sep/2025
Karyopharm Therapeutics USD -269.26M 30.33M Sep/2025
Ligand Pharmaceuticals USD 950.17M 121.64M Sep/2025
MacroGenics USD 67M 20.38M Sep/2025
Merck USD 51.85B 2.79B Sep/2025
Pacira USD 727.21M 30.55M Sep/2025
Pfizer USD 92.8B 4.11B Sep/2025
Rigel Pharmaceuticals USD 117.61M 35.67M Sep/2025
Sangamo BioSciences USD 19.6M 14.7M Jun/2025
Veracyte USD 1.26B 36.61M Sep/2025